These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1569667)

  • 1. Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure.
    Gerstenberg TC; Metz P; Ottesen B; Fahrenkrug J
    J Urol; 1992 May; 147(5):1277-9. PubMed ID: 1569667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction.
    McMahon CG
    Int J Impot Res; 1996 Dec; 8(4):233-6. PubMed ID: 8981173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents.
    Kiely EA; Bloom SR; Williams G
    Br J Urol; 1989 Aug; 64(2):191-4. PubMed ID: 2765789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study.
    Dinsmore WW; Gingell C; Hackett G; Kell P; Savage D; Oakes R; Frentz GD
    BJU Int; 1999 Feb; 83(3):274-9. PubMed ID: 10233493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate.
    Shah PJ; Dinsmore W; Oakes RA; Hackett G
    Curr Med Res Opin; 2007 Oct; 23(10):2577-83. PubMed ID: 17875241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double blind, placebo controlled study of intracavernosal vasoactive intestinal polypeptide and phenotolamine mesylate in a novel auto-injector for the treatment of non-psychogenic erectile dysfunction.
    Sandhu D; Curless E; Dean J; Hackett G; Liu S; Savage D; Oakes R; Frentz G
    Int J Impot Res; 1999 Apr; 11(2):91-7. PubMed ID: 10356669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracavernous drug-induced erections in the management of male erectile dysfunction: experience with 100 patients.
    Sidi AA; Cameron JS; Duffy LM; Lange PH
    J Urol; 1986 Apr; 135(4):704-6. PubMed ID: 2421014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracavernous self-injection for impotence: a long-term therapeutic option? Experience in 78 patients.
    Girdley FM; Bruskewitz RC; Feyzi J; Graversen PH; Gasser TC
    J Urol; 1988 Nov; 140(5):972-4. PubMed ID: 3172370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impotence: treatment by autoinjection of vasoactive drugs.
    Williams G; Mulcahy MJ; Kiely EA
    Br Med J (Clin Res Ed); 1987 Sep; 295(6598):595-6. PubMed ID: 3117249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracavernous injection of vasoactive drugs, an alternative for treating impotence in spinal cord injury patients.
    Wyndaele JJ; de Meyer JM; de Sy WA; Claessens H
    Paraplegia; 1986 Oct; 24(5):271-5. PubMed ID: 3774363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence.
    Zorgniotti AW; Lefleur RS
    J Urol; 1985 Jan; 133(1):39-41. PubMed ID: 2578067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracavernous self-injection with phentolamine and papaverine for the treatment of impotence.
    Gasser TC; Roach RM; Larsen EH; Madsen PO; Bruskewitz RC
    J Urol; 1987 Apr; 137(4):678-80. PubMed ID: 3550149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y; Lidgi S; Moskovitz B; Levin RD
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction.
    Dinsmore WW; Wyllie MG
    BJU Int; 2008 Sep; 102(8):933-7. PubMed ID: 18485029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.
    Lee LM; Stevenson RW; Szasz G
    J Urol; 1989 Mar; 141(3):549-50. PubMed ID: 2918589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The change of penile blood thromboxane B2 and prostacyclin after intracavernous injection of vasoactive drugs for the treatment of arteriogenic impotence.
    Lin JS; Chang WC; Lui SM
    Proc Natl Sci Counc Repub China B; 1994 Jan; 18(1):12-6. PubMed ID: 8029369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasoactive intestinal peptide/phentolamine. Invicorp, vasopotin.
    Drugs R D; 1999 Dec; 2(6):436-8. PubMed ID: 10763461
    [No Abstract]   [Full Text] [Related]  

  • 18. Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.
    Larsen EH; Gasser TC; Bruskewitz RC
    J Urol; 1987 Feb; 137(2):292-3. PubMed ID: 3806824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intracavernous infusion of drugs].
    Bellorofonte C; Dell'Acqua S; Ruoppolo M; Zaatar C; Tombolini P
    Arch Ital Urol Nefrol Androl; 1992 Sep; 64(3):251-4. PubMed ID: 1439852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self intra-cavernous injections as a successful treatment in pure neurogenic impotence.
    Greco E; Balbi PP; Virag R
    Riv Neurol; 1991; 61(1):35-8. PubMed ID: 1857921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.